Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)
Open Access

Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study

Christine E. Mona, Matthias R. Benz, Firas Hikmat, Tristan R. Grogan, Katharina Lückerath, Aria Razmaria, Rana Riahi, Roger Slavik, Mark D. Girgis, Giuseppe Carlucci, Kimberly A. Kelly, Samuel W French, Johannes Czernin, David W. Dawson and Jeremie Calais
Journal of Nuclear Medicine November 2021, jnumed.121.262426; DOI: https://doi.org/10.2967/jnumed.121.262426
Christine E. Mona
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias R. Benz
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Firas Hikmat
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tristan R. Grogan
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katharina Lückerath
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aria Razmaria
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rana Riahi
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Slavik
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark D. Girgis
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Carlucci
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly A. Kelly
2 University of Virginia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel W French
3 UCLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Dawson
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
1 University of California Los Angeles, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Fibroblast activation protein (FAP)-expressing cancer-associated fibroblasts confer treatment resistance, promote metastasis and immunosuppression. Because FAP is overexpressed in many cancers, radiolabeled molecules targeting FAP are studied for their use as pan-cancer theranostic agents. This study aims to establish the spectrum of FAP expression across various cancers by immunohistochemistry and to explore whether gallium-68 FAPi-46 (68Ga-FAPi-46) PET biodistribution faithfully reflects FAP expression from resected cancer and non-cancer specimens. Methods: We conducted a FAP expression screening by using immunohistochemistry on a pan-cancer human tissue microarray (TMA) (141 patients, 14 different types of cancer) and an interim analysis of a prospective exploratory imaging trial in cancer patients. Volunteer patients underwent one whole body 68Ga-FAPi-46 PET/CT scan and subsequently, surgical resection of their primary tumor and/or metastasis. 68Ga-FAPi-46 PET maximum standardized uptake value (SUVmax and SUVmean) was correlated with FAP immunohistochemistry score in cancer and non-cancer tissues for each patient. Results: FAP was expressed across all 14 cancers types on TMA with variable intensity and frequency, ranging from 25 to 100% (mean 76.6±25.3%). Strong FAP expression was observed in 50-100% of cancers of the bile duct, bladder, colon, esophagus, stomach, lung, oropharynx, ovary and pancreas. Fifteen patients with various cancer types (colorectal (n = 4), head and neck (n = 3), pancreas (n = 2), breast (n = 2), stomach (n = 1), esophagus (n = 2) and uterus (n = 1)) underwent surgery following their 68Ga-FAPi-46 PET/CT scan within a mean time interval of 16.1±14.4 days. 68Ga-FAPi-46 SUVs and immunohistochemistry scores were higher in cancer than in normal tissue: mean SUVmax 7.7 vs 1.6 (p<0.001), mean SUVmean 6.2 vs 1.0 (p<0.001) and mean FAP immunohistochemistry score 2.8 vs 0.9 (p<0.001). FAP immunohistochemistry scores strongly correlated with 68Ga-FAPi 46 SUVmax and SUVmean: r=0.781 (95%CI 0.376-0.936; p<0.001) and r=0.783 (95%CI 0.379-0.936; p<0.001), respectively. Conclusion: In this interim analysis of a prospective exploratory imaging trial, 68Ga-FAPi-46 PET biodistribution across multiple cancers strongly correlated with FAP tissue expression. These findings support further exploration of FAPi PET as a pan-cancer imaging biomarker for FAP expression and stratification tool for FAP- targeted therapies.

  • Immunoassay
  • Molecular Imaging
  • PET/CT
  • 68Ga-FAPi-46
  • Fibroblast Activation Protein
  • Immunohistochemistry
  • PET/CT
  • Pan-Cancer

Footnotes

  • Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: https://jnm.snmjournals.org/page/permissions.

  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (7)
Journal of Nuclear Medicine
Vol. 63, Issue 7
July 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study
Christine E. Mona, Matthias R. Benz, Firas Hikmat, Tristan R. Grogan, Katharina Lückerath, Aria Razmaria, Rana Riahi, Roger Slavik, Mark D. Girgis, Giuseppe Carlucci, Kimberly A. Kelly, Samuel W French, Johannes Czernin, David W. Dawson, Jeremie Calais
Journal of Nuclear Medicine Nov 2021, jnumed.121.262426; DOI: 10.2967/jnumed.121.262426

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study
Christine E. Mona, Matthias R. Benz, Firas Hikmat, Tristan R. Grogan, Katharina Lückerath, Aria Razmaria, Rana Riahi, Roger Slavik, Mark D. Girgis, Giuseppe Carlucci, Kimberly A. Kelly, Samuel W French, Johannes Czernin, David W. Dawson, Jeremie Calais
Journal of Nuclear Medicine Nov 2021, jnumed.121.262426; DOI: 10.2967/jnumed.121.262426
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • Diagnostic accuracy of 99mTc-Sestamibi SPECT/CT for characterization of solid renal masses
  • C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma
  • Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy
Show more Clinical Investigations (Human)

Clinical (Molecular Imaging: Molecular Biology)

  • Factors for differential outcome across cancers in clinical molecular-targeted fluorescence imaging
  • Phase 1 Evaluation of 11C-CS1P1 to Assess Safety and Dosimetry in Human Participants
Show more Clinical (Molecular Imaging: Molecular Biology)

Similar Articles

Keywords

  • Immunoassay
  • Molecular Imaging
  • PET/CT
  • 68Ga-FAPi-46
  • fibroblast activation protein
  • immunohistochemistry
  • Pan-Cancer
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire